Shigellosis, the acute enteric infection caused by bacteria of the genus Shigella, has a worldwide distribution with an estimated annual incidence of 164.7 million cases, of which 163.2 million occur in developing countries, and 1.1 million deaths. Sixty-nine percent of all episodes and 61 percent of all Shigella-related deaths involve children younger than 5 years old. In the United States, 10,000 to 15,000 cases of shigellosis are reported each year. Although usually confined to the colonic mucosa, shigellosis sometimes can cause extraintestinal complications. Recent publications have shed light on the clinical characteristics of Shigella-induced bacteremia, surgical complications, urogenital symptoms, and neurologic manifestations, and on the unique manifestations in the neonatal period. The mainstay of treatment of shigellosis in children is correction of the fluid and electrolyte loss, which often is achieved by the administration of oral rehydration solutions. Appropriate antibiotic therapy shortens the duration of both clinical symptoms and fecal excretion of the pathogen. However, the increasing antimicrobial resistance of shigellae worldwide constitutes a major problem. Regarding the pathophysiology of shigellosis and its complications, recent data not only elucidated the molecular mechanisms involved but also linked manifestations of disease to the interplay of bacterial virulence factors and host responses. The improved understanding of the pathophysiology is hoped to lead to innovative therapeutic approaches against shigellosis and new generations of vaccine candidates. Semin Pediatr Infect Dis 15:246-252
S
higella is a genus of gram-negative bacilli that causes human gastrointestinal infections, sometimes with extraintestinal manifestations. 1 Four species (serogroups) are defined on the basis of serologic or biochemical reactions, namely, Shigella dysenteriae, serogroup A; Shigella flexneri, serogroup B; Shigella boydii, serogroup C; and Shigella sonnei, serogroup D. 1, 2 Species classification has important therapeutic implications because the species differ in both geographic distribution and antimicrobial susceptibility. 1, [3] [4] [5] In developed countries, S. sonnei is the most common species; reports from several locations show an increase in its relative prevalence in the last several years. 2, 4, [6] [7] [8] [9] In developing countries, S. flexneri is most common, with outbreaks that often are caused by S. dysenteriae. 1, 2, 9 The serogroups are further classified into at least 37 serotypes and 13 subserotypes. 1, 2 To determine the global burden of Shigella infections, Kotloff and coworkers 9 analyzed published reports from various locations and then estimated the number of cases worldwide according to the world's population as categorized into developed and developing countries and into age groups. 9 They found that the annual number of Shigella episodes throughout the world was 164.7 million, of which 163.2 million occurred in developing countries, with 1.1 million deaths. 9 Sixty-nine percent of episodes and 61 percent of all shigellosis-related deaths involved children younger than 5 years of age. According to surveillance reports of the Centers for Disease Control and Prevention, 10,000 to 15,000 cases of shigellosis have been documented each year during the last 30 years in the United States, for annual incidence rates of 5 to 10 per 100,000. 7 During this period, the relative prevaPathophysiology A key element in the pathogenesis of shigellosis is the ability of the bacteria to invade colonic mucosa. The invasion process depends on a 210-to 220-Kb plasmid, which is necessary, but not sufficient, for full virulence. 2, 10, 11 New data not only have elucidated the molecular mechanisms involved but also have revealed that manifestations of disease depend on the interplay of bacterial virulence factors and host responses, which results in inflammation. 12, 13 In addition, new insights have been reported on the cellular and molecular effectors of the innate immune system that eradicate the bacteria during primary infection and prevent systemic dissemination, sometimes at the price of local tissue destruction in the colon. 11, [14] [15] [16] 
Shigella Determinants of Pathogenicity

Virulence Plasmid
Sequencing the virulence plasmid of the S. flexneri 5a strain M90T has allowed investigators to identify the genes encoding approximately 25 proteins secreted by the type III secretion system. 16 This secretion system, like that in some other gram-negative bacteria, translocates the Shigella effector molecules from the bacterial cytoplasm to the membrane and cytoplasm of the host cell. 17 A 31-kb segment of the virulence plasmid, called the entry region or ipa/mxi-spa locus, comprises the pathogenicity island, which actually is sufficient for entry of Shigella into intestinal epithelial cells, for apoptotic death of macrophages, and for activation of polymorphonuclear leukocytes. 18, 19 The island is organized into two divergently transcribed operons. 15, 18 One of the regions of the virulence plasma that is most extensively studied is the invasive plasmid antigen (ipa) region. 11, 18 It contains four genes, ipaA to ipaD, that encode four proteins, IpaA to IpaD, necessary for invasion. 11, 16, 20 After the shigellae contact the host cells, IpaB and IpaC are inserted as a single complex into the host membrane to form a 25A pore, through which the other invasive proteins are transported. 21 IpaB is essential for inducing apoptosis in macrophages; 13 IpaB combined with IpaC, together with cytoplasmic chaperon IpgC, are required for lysis of the cell membrane, which is needed for cell-to-cell spread. 22 The icsA (virG), virK, and sopA (icsP) genes play a role in the ability of shigellae to move within the cytoplasm of infected cells and to spread to other cells. 23 They encode, respectively, the outer membrane protein directly involved in intracellular spread, 24 the protein required for proper localization of icsA, 25 and the outer membrane protease that causes cleavage of icsA. 26 The virF gene regulates the virB locus, which is required for positive regulation of the ipa genes. The inv region is required for orientation of the Ipa proteins into the outer membrane of the bacteria. 11, 27 The function of the 5-copy ipaH gene has not been clarified yet.
Chromosomal Genes
Several chromosomal loci participate in the pathogenic process by complementing the core virulence of the invasion plasmid genes and are, therefore, needed for full virulence. They can be categorized into two groups:
1. Genes regulating the expression of the plasmid virulence genes. The virR gene encodes a histone-like molecule controlling the temperature-dependent expression of the Ipa and Mxi-Spa proteins, and the keratoconjunctivitis provocation (kcpA) gene positively regulates virG. 11,28 2. Genes needed for bacterial survival in the intestine and for resisting host defense mechanisms, such as those encoding lipopolysaccharides (LPS) and siderophores. Shigellae lacking complete LPS ("rough colonies") are avirulent. 2 
Shigella Toxins
Shiga toxin, encoded chromosomally and found mainly in S. dysenteriae serotype 1, is a potent protein-synthesis inhibitor that targets primarily the vascular endothelium. 29, 30 This toxin mediates the severe complication of hemolytic-uremic syndrome. 29, 31 A similar syndrome may be seen after infections with enterohemorrhagic Escherichia coli, which produce closely related toxins. 30, 31 In addition, Shiga toxin might play a role in the increased duration and severity of the diarrhea caused by S. dysenteriae serotype 1. 2, 32 Shigella spp. also produce two enterotoxins, ShET-1 and ShET-2. 33 ShET-1 is produced mainly by S. flexneri serotype 2a, whereas ShET-2 is produced by all Shigella spp. 33 These enterotoxins may contribute to the high-volume, watery diarrhea often seen in the initial stages of the disease.
Host Responses to Shigella Infection
Interactions of shigellae with host cells trigger inflammatory responses that lead to the histopathological changes that occur in the gut and the clinical presentation of shigellosis. 12, 15 Cytokine and chemokine responses have been shown by immunohistochemistry studies of rectal samples both in the sera and locally. 12, 34 Although host responses cause the inflammation, they also are mandatory for controlling the infection. 16 In a murine model, natural killer cell-mediated interferon-gamma production was found to be essential for host resistance to shigellosis. 14 Because the responses of the various host cells to Shigella infection are somewhat distinct, they are discussed briefly below.
Shigella and Intestinal Epithelial Cells
Shigellae cross the colonic epithelium through M cells in the follicle-associated epithelium overlying the Peyer patches. 2, 15 At the dome area of the lymphoid follicle, the bacteria are phagocytized by macrophages, which are killed by apoptosis. 13, 35 With this strategy, shigellae reach the subepithelial tissue and invade the colonic epithelial cells through their basolateral surface. 11 During the initial step of the entry process, shigellae induce actin polymerization in the epithelial cells with the formation of filopodes. 36 The process involves activation of the Rho family of GRPases. 36, 37 After entry, the bacteria disrupt their membrane-bound vacuole, proliferate in the cytoplasm, and use the actin-based motility, which is dependent on the IcsA (virG) protein. 11, 38 This process enables their spread to neighboring cells by the formation of finger-like protrusions. 15 In addition, intracellular shigellae program the colonic epithelial cells to express pro-inflammatory cytokines, such as interleukin (IL)-6 and IL-8, augmenting the local inflammation. 12, 39, 40 
Shigella and Macrophages
After crossing the colonic epithelium through the M cells, shigellae are taken up by local macrophages. They later escape from the phagosome and within 2 hours induce apoptosis of the macrophages and an inflammatory reaction. 13, 35, 40 IpaB protein mediates the apoptosis by binding to caspase-1 or IL-1-␤-converting enzyme, which cleaves the proinflammatory cytokines IL-1-␤ and IL-18 into their mature form. 13, 41 This inflammatory response has been shown to be important for eradicating the infection. 15 
Shigella and Leukocytes
The massive recruitment of polymorphonuclear leukocytes is mediated mainly by postinvasion intracellular Shigella LPS via transcription factors. 15 The Shigella LPS also induce the trafficking of toll-like receptor 4 (TLR4), the dominant mediator of the innate immune response. 16, 42 The leukocyte transmigration disrupts the intestinal epithelium. 15 Although this disruption initially contributes to virulence by aiding bacterial invasion, it actually limits the infection to the mucosa and submucosa and ultimately eradicates it because the bacteria are killed by polymorphonuclear leukocytes. This process has been well demonstrated in the severe combined immunodeficiency deficient mouse-human intestinal xenograft model. 43 
Clinical Features
Symptoms appear abruptly after an incubation period of 12 hours to approximately 2 days and include high fever, generalized toxicity, anorexia, nausea, crampy abdominal pain, and diarrhea. 1, 3, 10 Typically, the diarrhea initially consists of high-volume watery stools (small bowel disease), which may be followed by frequent, small-volume, bloody, mucous stools associated with urgency and painful defecation (large bowel disease). 1, 10 In children, most cases (Ͼ50%) never progress to bloody stools, although in some patients, the initial stools are bloody. 1, 3, 10 Extraintestinal Complications of Shigellosis Shigella Bacteremia Although usually confined to the colonic mucosa, shigellosis sometimes can cause extraintestinal complications. Bacteremia or septicemia rarely occurs during shigellosis and has been reported mainly in developing countries. 2, 44 For example, according to one study from Bangladesh, 4 percent of patients with shigellosis had Shigella bacteremia. 44 Bacteremia occurred more frequently in malnourished young infants and in patients infected with S. dysenteriae serotype 1, and it was associated with a significant mortality rate. A recent study from southern Israel described 15 children with Shigella bacteremia. 45 Mean age was 20 months; 13 patients (87%) failed to gain weight. Most (87%) of the isolates were S. flexneri, and none was S. dysenteriae serotype 1. No deaths were reported. 45 Of note is that in patients with acquired immunodeficiency syndrome (AIDS), 46 shigellosis is not only more common and more severe, but it also more often is associated with bacteremia. 47, 48 
Surgical Complications
Miron and coworkers 49 reviewed reports published during a 40-year period of 57 children with surgical complications of shigellosis. The complications were categorized into four groups: appendicitis with or without perforation (n ϭ 16, 28%); colonic perforation (n ϭ 10, 17%); intestinal obstruction (n ϭ 30, 53%); and intraabdominal abscesses (n ϭ 1, 2%). 49 Thirteen children (23%) died, often despite having received antimicrobial therapy. Many of the reports were from developed countries. 49 Pediatricians should be alerted to the risk of surgical complications of shigellosis, despite their rarity, because of the significant morbidity and mortality associated with a delayed diagnosis. Establishing a diagnosis often is hampered by the overlap of the signs and symptoms of shigellosis with those of peritonitis. 49 Some authors recommend avoiding laparotomy in the acute phase, even if signs of peritonitis are present, unless the patient has evidence of perforation. 49 Nonetheless, the pediatric surgeon should be consulted as soon as peritonitis is suspected.
Neurologic Manifestations
The neurologic manifestations of shigellosis usually are associated with a favorable outcome, although a study from Bangladesh noted a 29 percent mortality rate in affected children compared with 6 percent in those without neurologic symptoms. 50 Seizures are the most common neurologic manifestation, followed by lethargy and disorientation or coma, which often are referred to as encephalopathy. 1, 50, 51 In the minority of patients, the encephalopathy may be severe, unresponsive to antibiotic therapy, and fatal, even in developed countries. 52 The pathogenesis has not been elucidated. In developed countries, where hypoglycemia and electrolyte abnormalities do not play a significant pathogenic role, hyponatremia and early development of brain edema have been reported. 50, 51, 53 Complementary studies in a murine model documented the early development of brain edema and the major pathogenetic role of host response factors, such as tumor necrosis factor alpha, IL-1␤, and nitric oxide production. [54] [55] [56] 
Urogenital System
Although rare occurrences, vulvovaginitis and urinary tract infections caused by Shigella spp. are well-documented. 2, 57 Recent publications from developed countries highlight the problems in establishing the diagnosis and treating this infection. 57, 58 One case report from the United States described a prepubertal child with chronic vulvovaginitis caused by S. flexneri. 58 Vaginal discharge and bleeding were the presenting symptoms. Nonspecific vulvovaginitis and hemorrhagic cystitis initially were suspected, delaying the diagnosis. Furthermore, several empiric antimicrobial courses failed because of the antimicrobial resistance of the pathogen. Finally, after 3 years, 14-day treatment with ciprofloxacin led to resolution of the vaginal discharge. In another study, resistant S. sonnei caused a urinary tract infection that was cured only after treatment with a third-generation cephalosporin. 57 Thus, because of the rarity of their infections, their diagnoses often are delayed, and because of the antibiotic resistance of Shigellae, empiric therapy often fails. 57, 58 Neonatal Shigellosis A recent publication emphasized the unique problem of shigellosis in the neonatal period. 59 Newborn infections account for only 0.6 percent of all cases of shigellosis in the 0-to 10-year age group. Only 1.6 percent of all infants exposed to the infection become ill. 2, 4, 59 This finding is explained by the presence of maternal protective factors that pass through the placenta or are transferred during breastfeeding. 2, 60 Neonates with shigellosis may have only low-grade fever with mild diarrhea, often not bloody. Complications, however, occur more commonly than in older children and include septicemia, meningitis, dehydration, colonic perforation, and toxic megacolon. 59 The mortality rate also is twice as high as in older children, reaching 30 to 40 percent in developing countries, although less than 1 percent in developed regions. 59 On logistic regression analysis, predictors of infant mortality in developing countries were gramnegative bacteremia, hyponatremia, hypoproteinemia, and ileus. 59 
Diagnosis
Stool culture to isolate the pathogen is still the cornerstone of diagnosis. 2 This technique, however, has certain limitations: it takes a few days, the organisms may not survive transportation, sensitivity is not higher than 80 percent, and the culture may become negative in children given previous antibiotic therapy. 2 Additional diagnostic techniques show promise, but they have not been incorporated into practice yet. One large study (n ϭ 300) reported that improved direct polymerase chain reaction of stool specimens increased diagnosis by 50 percent compared with culture. 61 Other authors successfully identified shigellae by microarrays using the gyrB genes. 62 This novel approach also renders it possible to identify simultaneously other enteric pathogens, such as Salmonella spp. and diarrheogenic Escherichia coli. 62 Immune assay with monoclonal antibodies to the IpaC protein detected both Shigella spp. and enteroinvasive E. coli in 165 stool specimens, with high sensitivity and specificity. 63 
Treatment
Fluids and Nutrition
The mainstay of treatment of shigellosis in children is correction of the fluid and electrolyte loss, which often can be achieved by administering oral rehydration solutions. 2, 64 Early feeding, even with a high-protein diet, is important, especially in developing countries, to prevent malnutrition and encourage optimal growth. 65 
Antimicrobial Therapy
Appropriate antimicrobial therapy of shigellosis shortens the duration of fever and diarrhea, and it apparently also reduces the risk of developing complications. 10 Concomitantly, the duration of excretion of the pathogen in stools is shortened significantly, thereby reducing the spread of infection. 10, 66 However, the increasing antimicrobial resistance of shigellae constitutes a major problem. 10 Although initially susceptible, most Shigella isolates currently are resistant to ampicillin and trimethoprim-sulfamethoxazole (TPM-SMX). These antimicrobial agents often are recommended for the treatment of shigellosis, 5 but they currently are inappropriate for empiric therapy unless local microbiologic data suggest susceptibility. Table 1 [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] shows the percent of resistance by geographic location. One should note that these values are based on all Shigella isolates; S. sonnei, which is the most prevalent species in developed countries and relatively more common in children, 6 tends to be more resistant than is S. flexneri. 5 For example, in Israel, between 1998 and 2000, 97 percent of S. sonnei were resistant to TMP-SMX, compared with 69 percent of S. flexneri (P Ͻ 0.0001). 5 
Quinolones
Although nalidixic acid proved to be efficacious against shigellosis in one pediatric clinical study, other studies from Bangladesh, Hong Kong, and Taiwan reported high resistance to this agent (Table 1) . 69, 70, 73 Rates of resistance in most developed countries are below 2 percent (Table 1) . 5, 67, 74 The new fluoroquinolones appear to have a high clinical and microbiological efficacy against shigellosis and frequently are used in adults with suspected Shigella infections. 10, 66, 69 They are not approved for children younger than 18 years of age because of a risk of drug-induced damage to the immature joints. 66 Some authors question this policy, owing to the proven effectiveness of quinolones in children 77, 78 and the apparent safety of a short course. 10 Reduced susceptibility of Shigella spp., especially S. dysenteriae serotype 1, to fluoroquinolones has been reported and may be mediated by a proton motive force (pmf)-dependent efflux system. 79, 80 Cephalosporins First-and second-generation cephalosporins, such as cephalexin, cefamandole, and cefaclor, are ineffective against shig-ellosis, often despite the susceptibility of the pathogen in vitro. 10 Their main limitation is the delayed fecal eradication of shigellae. Third-generation cephalosporins hold promise. Among this group, ceftriaxone has been the one investigated most extensively. Response was excellent, with two doses of ceftriaxone being as effective as five. 10, 81 Cefixime was effective in children infected mostly with S. sonnei, but it was less effective in adults with severe shigellosis caused mostly by S. dysenteriae and S. flexneri. 10, 82 Resistance to third-generation cephalosporins, mediated by extended-spectrum beta-lactamases, has been reported in several locations. 10, 83 Azithromycin Azithromycin, an azalide with a broad spectrum of antimicrobial activity, was found to be efficacious in adults with shigellosis. 69 In a comparison of azithromycin and cefixime in a controlled study of 75 children with culture-proven shigellosis in Paraguay, 84 researchers noted a similar clinical efficacy for the two drugs but a better bacteriologic efficacy of azithromycin (P Ͻ 0.01), perhaps due to its better penetration into cells. 84 In summary, two parenteral doses of ceftriaxone is suggested as the treatment of choice for severe shigellosis in children, especially hospitalized patients. Oral treatment of milder cases is more problematic and depends on local resistance patterns. One should remember that many of the agents discussed here are not approved yet by the Food and Drug Administration for the treatment of shigellosis.
Prevention
Clean running water, appropriate sanitation, control of flies, good personal hygiene, and breastfeeding are the main measures to reduce the spread of shigellosis. 2 Despite continuing efforts for the last 50 years, researchers so far have failed to produce a vaccine against Shigella spp. Several strategies to develop a Shigella vaccine are being studied. The current status of vaccine development is addressed elsewhere in this volume with the other enteric vaccines (Nataro). 
